000			02305 a2200649 4500
005			20250516113531.0
264		0	_c20130212
008			201302s 0 0 eng d
022			_a1552-4469
024	7		_a10.1038/nchembio.1085 _2doi
040			_aNLM _beng _cNLM
100	1		_aWinter, Georg E
245	0	0	_aSystems-pharmacology dissection of a drug synergy in imatinib-resistant CML. _h[electronic resource]
260			_bNature chemical biology _cNov 2012
300			_a905-912 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAniline Compounds _xpharmacology
650	0	4	_aAnimals
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xpharmacology
650	0	4	_aApoptosis _xdrug effects
650	0	4	_aBenzamides _xpharmacology
650	0	4	_aCell Line, Tumor
650	0	4	_aCell Survival _xdrug effects
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDown-Regulation _xdrug effects
650	0	4	_aDrug Resistance, Neoplasm _xdrug effects
650	0	4	_aDrug Synergism
650	0	4	_aFusion Proteins, bcr-abl _xantagonists & inhibitors
650	0	4	_aImatinib Mesylate
650	0	4	_aLeukemia, Myelogenous, Chronic, BCR-ABL Positive _xdrug therapy
650	0	4	_aMice
650	0	4	_aNitriles _xpharmacology
650	0	4	_aPiperazines _xpharmacology
650	0	4	_aProtein Kinase Inhibitors _xpharmacology
650	0	4	_aProteomics
650	0	4	_aProto-Oncogene Proteins c-myc _xantagonists & inhibitors
650	0	4	_aPyrazoles _xpharmacology
650	0	4	_aPyrimidines _xpharmacology
650	0	4	_aQuinolines _xpharmacology
650	0	4	_aStructure-Activity Relationship
650	0	4	_aSystems Biology
700	1		_aRix, Uwe
700	1		_aCarlson, Scott M
700	1		_aGleixner, Karoline V
700	1		_aGrebien, Florian
700	1		_aGridling, Manuela
700	1		_aMüller, André C
700	1		_aBreitwieser, Florian P
700	1		_aBilban, Martin
700	1		_aColinge, Jacques
700	1		_aValent, Peter
700	1		_aBennett, Keiryn L
700	1		_aWhite, Forest M
700	1		_aSuperti-Furga, Giulio
773	0		_tNature chemical biology _gvol. 8 _gno. 11 _gp. 905-912
856	4	0	_uhttps://doi.org/10.1038/nchembio.1085 _zAvailable from publisher's website
999			_c22145994 _d22145994